SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Castle Biosciences, Inc. (CSTL) News

Follow Castle Biosciences, Inc. (CSTL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CSTL Asset equity Sector Markets 90 days 13 Last 32.915 Updated Nov 06, 2026, 12:21 AM UTC Open live news feed Open CSTL chart & news
M Castle Biosciences Reports Quarterly Results Through September 30 A machine-generated LSEG earnings summary was published, but the supplied text contains no financial results. EQUITY | Nov 06, 2026, 12:21 AM UTC M Castle Biosciences Q3 Revenue Beats Estimates on TissueCypher Volume Growth EQUITY | Nov 05, 2026, 09:47 PM UTC M Castle Biosciences Reports Third-Quarter Loss of $4.1 Million EQUITY | Nov 05, 2026, 09:17 PM UTC M Castle Biosciences Reports Q3 Revenue of $102.9 Million, Raises 2026 Guidance Q3 2026 revenue rose 24% year over year, while TissueCypher test report volume increased 47%. Castle Biosciences raised full-year 2026 revenue guidance to $385–395 million, from a prior range. EQUITY | Nov 05, 2026, 09:06 PM UTC M Castle Biosciences sets Q3 2026 results webcast for Nov. 5 The company plans to release third-quarter 2026 financial results and host a webcast on Thursday, Nov. 5, 2026. EQUITY | Oct 15, 2026, 11:01 AM UTC H Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed int LIVE | Sep 24, 2026, 08:32 PM UTC L CSTL - Castle Biosciences to Open New Laboratory Facility in Scottsdale CSTL - Castle Biosciences to Open New Laboratory Facility in Scottsdale NEWS | Sep 22, 2026, 11:01 AM UTC L CSTL: TissueCypher and melanoma test growth, AI integration, and regulatory advances drive expansion Strong growth in molecular diagnostics, especially for TissueCypher, is supported by expanding sales teams and AI-driven technology. Regulatory progress and new evidence may drive future reimbursement and adoption, while NEWS | Sep 15, 2026, 04:49 PM UTC L CSTL: TissueCypher and DecisionDx tests drive growth, with AI and reimbursement advances supporting expansion Strong growth in molecular diagnostics, especially TissueCypher, is supported by robust margins and AI-driven innovation. Dermatology and gastroenterology segments are expanding, with new product launches and ongoing rei NEWS | Sep 15, 2026, 04:19 PM UTC L CSTL: TissueCypher's rapid growth and AI-driven advances position the business for strong future expansion Strong Q2 growth was driven by TissueCypher's 63% YoY volume increase and robust gross margins, with long-term market penetration modeled at 60%-65%. AI initiatives are enhancing test development and reimbursement, while NEWS | Sep 15, 2026, 04:00 PM UTC L CSTL - New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus CSTL - New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus NEWS | Sep 15, 2026, 11:02 AM UTC L CSTL - JAAD Publication Shows Improved Performance of DecisionDx®-SCC CSTL - JAAD Publication Shows Improved Performance of DecisionDx®-SCC EQUITY | Sep 09, 2026, 08:30 PM UTC L SciBase receives additional order from Castle Biosciences SciBase says it has received an additional order from Castle Biosciences to accelerate its ongoing clinical study and related preparations. EQUITY | Sep 08, 2026, 01:32 PM UTC L CSTL - Castle Biosciences to Participate in Upcoming Investor Conferences CSTL - Castle Biosciences to Participate in Upcoming Investor Conferences EQUITY | Aug 20, 2026, 11:01 AM UTC L Castle Biosciences approved for dual listing on Nasdaq Texas Castle Biosciences (CSTL) received approval for a dual listing on Nasdaq Texas, according to TradeXchange Newsdesk. REGULATION | Aug 17, 2026, 11:00 AM UTC L CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB EQUITY | Jul 31, 2026, 11:16 AM UTC H AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1 AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results EARNINGS | Jul 30, 2026, 08:34 PM UTC H COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results EARNINGS | Jul 30, 2026, 08:18 PM UTC L Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est Castle Biosciences (NASDAQ: CSTL ) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate. EARNINGS | Jul 30, 2026, 08:17 PM UTC L CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results EARNINGS | Jul 30, 2026, 08:06 PM UTC L CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expen CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expenses $106.616M, Q2 pretax profit $-1.69M EARNINGS | Jul 30, 2026, 08:05 PM UTC L CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test EQUITY | Jul 14, 2026, 08:30 PM UTC M CSTL Outperforms MIA CSTL's DecisionDx-Melanoma's i31-SLNB outperforms MIA Nomogram in identifying patients who may safely forgo sentinel lymph node biopsy EQUITY | Jun 25, 2026, 08:31 PM UTC M TNXP: Raymond James Initiates Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26 EQUITY | Jun 25, 2026, 12:44 PM UTC M CSTL: Roth Initiates Buy Roth Capital initiates coverage on Castle Biosciences with a Buy rating and a price target of $40 EQUITY | Jun 25, 2026, 10:39 AM UTC